Welcome to our dedicated page for Arch Biopartners news (Ticker: ACHFF), a resource for investors and traders seeking the latest updates and insights on Arch Biopartners stock.
Arch Biopartners Inc. (ACHFF) is a clinical-stage biotechnology company pioneering therapies for inflammation-related organ injuries. This page aggregates official news, press releases, and research updates related to their LSALT peptide development and clinical trials.
Investors and researchers will find timely updates on Phase II trial progress, academic partnerships, and regulatory milestones. Content spans clinical trial results, research collaborations, and biomedical innovation announcements, providing a comprehensive view of the company's scientific advancements.
Bookmark this page to stay informed about Arch Biopartners' developments in targeting inflammation injuries during cardiac surgery and other high-risk procedures. Check regularly for verified updates directly impacting the biopharmaceutical investment landscape.
Arch Biopartners Inc. (OTCQB: ACHFF) announced a successful increase in the maximum daily dose of its lead drug candidate, LSALT peptide, to 20 mg in a human trial in Australia. This trial confirmed the safety and tolerability of the new dosage, paving the way for a Phase II trial aimed at treating cardiac surgery-associated acute kidney injury (CS-AKI). Previously, LSALT peptide was administered at a maximum of 5 mg during a Phase II trial for COVID-19 patients. Arch is also advancing the production of 10,000 vials of LSALT peptide for future non-COVID trials, expected to be ready by May 2023. The trial took place at the Alfred Hospital in Melbourne, involving sixteen healthy volunteers. The new safety data will be included in a future IND application to the U.S. FDA.
FAQ
What is the current stock price of Arch Biopartners (ACHFF)?
What is the market cap of Arch Biopartners (ACHFF)?
